The Society of Surgical Oncology 2016 Choosing Wisely<sup>®</sup> guideline advises against routine sentinel lymph node biopsy in women ≥ 70 years with clinically node-negative, hormone receptor-positive/human epidermal growth factor receptor 2 (HER2)-negative invasive breast cancer receiving endocrine therapy. This evidence concerns the gene ERBB2 and invasive breast carcinoma.